Major Changes by the DOJ and SEC in FCPA Enforcements
Pharmaceutical companies need to ensure that their own operations and those of third parties comply with the risks surrounding FCPA and similar regulations. Otherwise, they risk costly fines, possible imprisonment of directors or managers, and loss of reputation, leading to irrevocable losses in revenue and market share.
Read this white paper to learn about:
CUSTOMER PORTAL